Doximity, Inc. $DOCS Shares Sold by Apella Capital LLC

Key Points

• Apella Capital LLC reduced its stake in Doximity, Inc. by 11.6% in the second quarter, holding 69,874 shares worth approximately $4.25 million after selling 9,165 shares.
• Doximity's recent earnings report showed an EPS of $0.36, surpassing estimates and marking a 15.2% year-over-year revenue increase.
• A number of analysts have raised their price targets for Doximity, with an average target of $67.00 and a consensus rating classified as Moderate Buy.

Apella Capital LLC decreased its position in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 11.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,874 shares of the company's stock after selling 9,165 shares during the period. Apella Capital LLC's holdings in Doximity were worth $4,253,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Doximity by 8.8% in the 1st quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company's stock worth $707,646,000 after buying an additional 990,923 shares during the last quarter. Invesco Ltd. boosted its holdings in Doximity by 54.8% in the 1st quarter. Invesco Ltd. now owns 1,969,326 shares of the company's stock worth $114,280,000 after buying an additional 696,923 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Doximity by 130.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,966,801 shares of the company's stock worth $114,133,000 after buying an additional 1,113,076 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its holdings in Doximity by 9.5% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,730,282 shares of the company's stock worth $100,408,000 after buying an additional 150,574 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Doximity by 8.2% in the 1st quarter. Bank of New York Mellon Corp now owns 1,137,912 shares of the company's stock worth $66,033,000 after buying an additional 86,135 shares during the last quarter. Hedge funds and other institutional investors own 87.19% of the company's stock.

Insider Buying and Selling at Doximity

In other news, Director Regina M. Benjamin sold 10,000 shares of the stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the sale, the director owned 16,618 shares in the company, valued at approximately $997,080. This represents a 37.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Timothy S. Cabral sold 10,000 shares of the stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00. Following the sale, the director owned 6,360 shares of the company's stock, valued at $381,600. This trade represents a 61.12% decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,000 shares of company stock worth $2,281,880 over the last 90 days. Corporate insiders own 31.30% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on DOCS shares. Truist Financial lifted their price objective on Doximity from $52.00 to $61.00 and gave the stock a "hold" rating in a report on Thursday, July 17th. Bank of America lifted their price objective on Doximity from $55.00 to $62.00 and gave the stock a "neutral" rating in a report on Wednesday, June 25th. JPMorgan Chase & Co. decreased their target price on shares of Doximity from $63.00 to $60.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 27th. Robert W. Baird raised their target price on shares of Doximity from $75.00 to $80.00 and gave the stock an "outperform" rating in a research note on Thursday, September 11th. Finally, Needham & Company LLC raised their target price on shares of Doximity from $67.00 to $75.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, Doximity presently has a consensus rating of "Moderate Buy" and a consensus price target of $67.42.

Doximity Stock Performance

NASDAQ DOCS traded down $0.02 during trading hours on Friday, hitting $73.58. The company had a trading volume of 435,417 shares, compared to its average volume of 2,192,419. Doximity, Inc. has a 1-year low of $40.15 and a 1-year high of $85.21. The company has a market cap of $13.78 billion, a PE ratio of 73.63, a price-to-earnings-growth ratio of 4.10 and a beta of 1.37. The business has a 50 day moving average of $64.51 and a 200-day moving average of $59.99.

Doximity (NASDAQ:DOCS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same period in the prior year, the firm earned $0.28 earnings per share. The firm's revenue was up 15.2% on a year-over-year basis. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. Sell-side analysts expect that Doximity, Inc. will post 0.99 earnings per share for the current fiscal year.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.